Eli Lilly has announced promising results from a late-stage clinical trial for its oral obesity medication, Foundayo, demonstrating a significant reduction in the severity of obstructive sleep apnea (OSA) in adults with obesity or who are overweight. The pharmaceutical giant is preparing to submit an application for U.S. approval of the daily pill for moderate-to-severe OSA by the end of the year.

These findings position Foundayo as a potential new treatment option for a condition that affects millions globally, with a substantial portion of sufferers undiagnosed. Obstructive sleep apnea, characterized by interrupted breathing during sleep due to airway blockage, is linked to serious health risks including hypertension, heart failure, and stroke. Current treatment options are limited, often relying on continuous positive airway pressure (CPAP) machines, which can be cumbersome for patients.

The trial involved two distinct studies. In the first, participants who were unable or unwilling to use CPAP therapy experienced an average reduction of 21.1 fewer apnea-hypopnea index (AHI) events per hour when taking Foundayo, compared to a 4.8 reduction in the placebo group. Furthermore, 31.5% of those on Foundayo achieved remission or improvement to mild OSA. The second study, which included patients already using CPAP therapy, also showed significant benefits, with Foundayo users experiencing an average of 18.3 fewer AHI events per hour compared to 5.5 in the placebo group, and 19.6% meeting criteria for remission or mild OSA.

Beyond its impact on AHI scores, Foundayo also demonstrated a notable reduction in the sleep apnea-specific hypoxic burden, a measure of oxygen desaturation during sleep. The pill also contributed to an average weight loss of approximately 11% across participants and showed a reduction in a marker of inflammation. While the safety profile was generally consistent with previous trials, gastrointestinal side effects like nausea and diarrhea were the most common, typically mild to moderate in severity.

Key Takeaways

• Eli Lilly's Foundayo obesity pill significantly reduced obstructive sleep apnea severity in late-stage trials.
• The company plans to seek U.S. approval for Foundayo as a treatment for OSA by year-end.
• The drug also showed benefits in weight loss and reduced sleep-related oxygen desaturation.

Editor’s Analysis & Impact

The successful trial results for Foundayo in treating obstructive sleep apnea represent a significant advancement for Eli Lilly and a potential paradigm shift in OSA management. By offering an oral medication that addresses both obesity and a major comorbidity like OSA, Lilly is tapping into a vast, underserved market. This development could challenge the dominance of CPAP machines and position GLP-1 based therapies as a multi-faceted solution for metabolic and respiratory health. The broader implications extend to the pharmaceutical industry, potentially spurring further research into similar combination therapies and highlighting the interconnectedness of metabolic health and sleep disorders.

Frequently Asked Questions

Q: What is obstructive sleep apnea (OSA)?
A: Obstructive sleep apnea is a common sleep disorder where breathing repeatedly stops and starts during sleep due to a blockage in the airway. This can lead to drops in oxygen levels and increased blood pressure, posing risks for serious health complications.

Q: How does Foundayo work for sleep apnea?
A: Foundayo, an oral GLP-1 receptor agonist, works by reducing the severity of obstructive sleep apnea, likely through a combination of weight loss and potential direct effects on airway tone and respiratory control. The trial measured its effectiveness by tracking the apnea-hypopnea index (AHI) and oxygen saturation levels during sleep.

Q: What are the common side effects of Foundayo?
A: The most frequently reported side effects of Foundayo are gastrointestinal in nature, including nausea, diarrhea, constipation, and vomiting. These are generally considered mild to moderate in severity, consistent with other medications in the GLP-1 class.